<?xml version="1.0" encoding="UTF-8"?>
<p>In high-income countries, antiretroviral therapy (ART) has improved the survival of persons living with HIV (PLHIV), resulting in declines in morbidity and mortality and a shift in the natural history of HIV disease [
 <xref rid="ref1" ref-type="bibr">1</xref>-
 <xref rid="ref3" ref-type="bibr">3</xref>]. With ART scale-up in the low-income and middle-income countries (LMICs), similar epidemiologic transitions are expected, resulting in an expanding and aging HIV population [
 <xref rid="ref4" ref-type="bibr">4</xref>,
 <xref rid="ref5" ref-type="bibr">5</xref>]. Since 2004, the US Presidentâ€™s Emergency Plan for AIDS Relief (PEPFAR), in collaboration with local governments, has established HIV prevention, care, and treatment programs in over 30 countries worldwide [
 <xref rid="ref6" ref-type="bibr">6</xref>], and the Global Fund to Fight HIV, Tuberculosis and Malaria has funded programs in more than 100 countries, including some PEPFAR-funded countries [
 <xref rid="ref7" ref-type="bibr">7</xref>]. Globally, the provision of ART accelerated dramatically over the past decade, supporting 19 million PLHIV on ART through June 2016. When the Joint United Nations Programme on AIDS (UNAIDS) [
 <xref rid="ref8" ref-type="bibr">8</xref>] 90-90-90 goals (90% of people with HIV diagnosed, 90% of them on ART, and 90% of them virally suppressed by 2020) are realized, AIDS-related opportunistic infections will become rare [
 <xref rid="ref9" ref-type="bibr">9</xref>], and noncommunicable diseases (NCDs) will become increasingly prevalent among PLHIV [
 <xref rid="ref10" ref-type="bibr">10</xref>-
 <xref rid="ref16" ref-type="bibr">16</xref>].
</p>
